New pharmacologic approaches in gastroesophageal reflux disease.
This article highlights current and emerging pharmacological treatments for gastroesophageal reflux disease (GERD), opportunities for improving medical treatment, the extent to which improvements may be achieved with current therapy, and where new therapies may be required. These issues are discussed in the context of current thinking on the pathogenesis of GERD and its various manifestations and on the pharmacologic basis of current treatments.
Division of Gastroenterology, HSC-4W8F, McMaster University Medical Centre, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada.
David
D
Armstrong
Daniel
D
Sifrim
D000700:Analgesics / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D063386:Cannabinoid Receptor Agonists; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D049630:Esophageal Sphincter, Lower / Q000187:drug effects; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D058786:GABA-B Receptor Agonists / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000187:drug effects; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D011188:Potassium / Q000378:metabolism; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000627:therapeutic use
D000700:Analgesics; D000863:Antacids; D063386:Cannabinoid Receptor Agonists; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D058786:GABA-B Receptor Agonists; D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D043882:Receptors, Cannabinoid; D011188:Potassium